Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Next Science Limited
  6. News
  7. Summary
    NXS   AU0000041329

NEXT SCIENCE LIMITED

(NXS)
  Report
Delayed Australian Stock Exchange  -  07:16:40 2023-02-06 pm EST
0.6900 AUD   +4.55%
02/01Transcript : Next Science Limited - Shareholder/Analyst Call
CI
2022Next Science Limited announced that it expects to receive AUD 10 million in funding from Walker Group Holdings Pty Limited
CI
2022Next Science Secures AU$10 Million in Convertible Notes; Shares Down 4%
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Next Science Limited Announces the Launch of Topical Collagen Products

10/18/2022 | 06:14pm EST

Next Science Limited announced the launch of topical collagen products (Collagen) to complement the company's BlastXTM product. To take this product to market more effectively, the company has established itself as, and been licensed and accredited by US Medicare as, a Durable Medical Equipment (DME) provider based in the State of Florida, USA. Biofilms are the major underlying problem in chronic, difficult to treat wounds.

The company's XBioTM technology-derived products disrupt biofilms in wounds and are at the core of its mission to heal patients and save lives. One product at the heart of this commitment is BlastXTM, developed for the management of wounds including various forms of chronic non-healing ulcers as well as other general and surgical wound infections. As part of its research and development program, the company continually explore how BlastXTM can complement and strengthen traditional wound healing support.

An example at the forefront of this program is the use of Collagen with BlastXTM to enhance patient outcomes. Combining BlastX TM with Collagen: The company is developing technology to combine BlastXTM with Collagen in both powder and sheet forms (the forms in which it is currently administered for wound care). The technology, which will fully preserve the efficacy of both BlastXTM and Collagen, is continuing through development towards submitting a FDA 510k application for an integrated BlastXTM Collagen product.

After much investigation, Next Science has determined that the most efficient and competitive way for a BlastXTM Collagen product to enter the market will be via the US DME structure, explained further below. The Company announces that it has completed the application process and received full accreditation to operate, and be reimbursed through US Medicare, as a DME provider based in the State of Florida, USA. This means that the Company is licensed to bill Medicare /Medicaid for the supply of approved products direct to patients and is now also holding a National Provider Identifier with Medicare.

The Medicare registration gives Next Science a licence to sell in 40 US States. The company will now review the process for registration in the remaining 10 States. BlastX TM /Collagen User Study: The company announces that commencing immediately, and simultaneously with the ongoing development of the integrated BlastXTM /Collagen product and the 510(k) application process, it will be distributing a Collagen product through the DME structure and undertake a user study on the combination of BlastXTM with Collagen.

The user study will provide strong clinical evidence for the combined use of the two wound care technologies. BlastXTM will be provided to patients enrolled in the user study who are prescribed Collagen treatment in order to add proven infection control to their healing strategy. Short series case studies have shown that augmenting Collagen treatment with BlastXTM will push a stalled surgical wound or unhealed pressure ulcer back to healing with wound closure shown to occur at between two and four weeks.

Standard wound care healing usually takes between twelve and sixteen weeks. In supplementing its portfolio with Collagen, the company is providing a complementary product to advance the healing of chronic wounds and at the same time, improving its wound care business economics as the use of Collagen materials is eligible for reimbursement. This means the company will receive a significant contribution towards marketing, sales, distribution and administration costs for BlastXTM.


ę S&P Capital IQ 2022
All news about NEXT SCIENCE LIMITED
02/01Transcript : Next Science Limited - Shareholder/Analyst Call
CI
2022Next Science Limited announced that it expects to receive AUD 10 million in funding fro..
CI
2022Next Science Secures AU$10 Million in Convertible Notes; Shares Down 4%
MT
2022Transcript : Next Science Limited Presents at ShareCafe Small Cap "Hidden Gem..
CI
2022Next Science's Collagen Products Secure Medicare Accreditation in the US; Shares Jump 8..
MT
2022Next Science Limited Announces the Launch of Topical Collagen Products
CI
2022Next Science Secures License for Wound Cleaning Product in Canada
MT
2022Next Science Limited Announces Health Canada Given Licensing Approval for XPERIENCE
CI
2022Transcript : Next Science Limited, H1 2022 Earnings Call, Aug 25, 2022
CI
2022Next Science Limited Reports Earnings Results for the Half Year Ended June 30, 2022
CI
More news
Financials (USD)
Sales 2022 11,3 M - -
Net income 2022 -11,0 M - -
Net cash 2022 9,56 M - -
P/E ratio 2022 -10,1x
Yield 2022 -
Capitalization 97,4 M 97,4 M -
EV / Sales 2022 7,77x
EV / Sales 2023 4,84x
Nbr of Employees -
Free-Float 47,5%
Chart NEXT SCIENCE LIMITED
Duration : Period :
Next Science Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEXT SCIENCE LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,45 $
Average target price 0,90 $
Spread / Average Target 99,3%
EPS Revisions
Managers and Directors
Judith Mitchell Chief Executive Officer, Director & MD
Jacqueline Butler Chief Financial Officer
Mark R. Compton Independent Non-Executive Chairman
Matthew Myntti Chief Technology Officer
Jeanne Lee VP-Regulatory Affairs & Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
NEXT SCIENCE LIMITED-8.76%93
JOHNSON & JOHNSON-6.82%430 370
ELI LILLY AND COMPANY-7.31%322 186
NOVO NORDISK A/S0.37%309 611
ROCHE HOLDING AG-2.81%269 030
MERCK & CO., INC.-7.22%260 994